1.
Harefuah
; 163(6): 397, 2024 Jun.
Artigo
em Hebraico
| MEDLINE
| ID: mdl-38884296
RESUMO
INTRODUCTION: Imatinib is a tyrosine kinase inhibitor and is used for the treatment of chronic myeloid leukemia (CML) since 2002. We present a patient who suffered from fluid retention and periorbital edema secondary to this drug.